We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
- Authors
Podzamczer, Daniel; Andrade-Villanueva, J; Clotet, B; Taylor, S; Rockstroh, J K; Reiss, P; Domingo, P; Gellermann, H J; de Rossi, L; Cairns, V; Soriano, V
- Abstract
Dyslipidaemic effects of antiretrovirals (ARVs) may contribute to increased cardiovascular risk (CR) in HIV-1-infected patients. The ARTEN (atazanavir/ritonavir on a background of tenofovir and emtricitabine vs. nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naïve HIV-1-infected patients. Lipid profiles and CR from baseline to week 48 are reported.
- Publication
HIV medicine, 2011, Vol 12, Issue 6, p374
- ISSN
1468-1293
- Publication type
Journal Article
- DOI
10.1111/j.1468-1293.2011.00917.x